loading...| Preferred Name |
Liarozole |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1433 |
| ALT_DEFINITION |
An anticancer drug that promotes differentiation by increasing the levels of retinoic acid within the tumor. |
| CAS_Registry |
115575-11-6 |
| Chemical_Formula |
C17H13ClN4 |
| code |
C1433 |
| Concept_In_Subset | |
| Contributing_Source |
FDA |
| DEFINITION |
An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis. |
| FDA_UNII_Code |
K0Q29TGV9Y |
| FULL_SYN |
R 75251 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)- Liazal R-61405 |
| Has_Salt_Form | |
| label |
Liarozole |
| Legacy_Concept_Name |
Liarozole |
| Preferred_Name |
Liarozole |
| prefixIRI |
C1433 |
| prefLabel |
Liarozole |
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
| UMLS_CUI |
C0165479 |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| http://purl.obolibrary.org/obo/CHEBI_135316 | Chemical Entities of Biological Interest Ontology | LOOM | |
| http://purl.bioontology.org/ontology/MESH/C061121 | Medical Subject Headings | LOOM |